Cerulean Pharma Cmn (CERU) 2.68 $CERU Cerulean to Host

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cerulean Pharma Cmn (CERU) 2.68 $CERU

Cerulean to Host Second Quarter 2016 Conference Call on August 4
BusinessWire - Thu Jul 28, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the second quarter 2016 on August 4.
CERU: 2.68 (-0.21)

Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer
BusinessWire - Tue Jul 19, 6:30AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Cerulean's lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer.
CERU: 2.68 (-0.21)

Cerulean Pharma (CERU) Worth a Look: Stock Gains 9.1%
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 7:45AM CDT
Cerulean Pharma Inc. (CERU) was a big mover last session, as the company saw its shares rise over 9% on the day.
CERU: 2.68 (-0.21), AKAO: 3.59 (-0.06)

Cerulean Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors
BusinessWire - Thu Jun 23, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in the Phase 2a stage of an ongoing Phase 1/2a clinical trial of CRLX301 in patients with advanced solid tumors.
CERU: 2.68 (-0.21)

Cerulean Announces Publication in Cancer Research
BusinessWire - Wed Jun 22, 8:20AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of preclinical proof of concept data for its lead compound, CRLX101, in the journal Cancer Research. The publication highlights that CRLX101 demonstrated strong antitumor activity, as monotherapy and in combination with Avastin(R) (bevacizumab), leading to complete tumor regression, reduced metastasis, and extended survival of mice with metastatic disease. These preclinical results were derived from mouse models of orthotropic primary triple-negative breast tumor xenografts, including a patient-derived xenograft and a model of post-surgical, advanced metastatic breast cancer. The article was published online.
CERU: 2.68 (-0.21)

Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Susan L. Kelley, M.D. to the Company's Board of Directors.
IMDZ: 7.29 (-0.34), CERU: 2.68 (-0.21)

Cerulean Announces Manuscript Published in Annals of Oncology
BusinessWire - Thu Jun 09, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the manuscript of clinical data for its lead compound, CRLX101, in the journal Annals of Oncology. The manuscript highlights results from an open-label, single arm Phase 1b/2 investigator-sponsored trial (IST) of CRLX101 in combination with Avastin(R) (bevacizumab) in patients with metastatic renal cell carcinoma (RCC). The trial achieved its primary endpoint of establishing a recommended Phase 2 dose and showed preliminary anti-tumor activity. The article is available online. Results from the trial also were presented at the 2015 American Society of Clinical Oncology annual meeting on June 1, 2015 and at the 2015 International Kidney Cancer Symposium on November 4, 2015.
CERU: 2.68 (-0.21)

Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference
BusinessWire - Thu May 19, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the Company will present in an oral session Phase 1b results of an ongoing clinical trial of CRLX101 in combination with weekly paclitaxel in patients with relapsed ovarian cancer at the Gynecologic Oncology 2016 Conference being held May 19-21 in San Antonio, Texas. This trial is being conducted by Cerulean in collaboration with the GOG Foundation, Inc.
CERU: 2.68 (-0.21)

Cerulean to Present at the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:12PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced a scheduled poster presentation on CRLX301 at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, at McCormick Place in Chicago.
CERU: 2.68 (-0.21)

Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA(TM)
BusinessWire - Tue May 10, 6:30AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA(TM) (olaparib) in patients with advanced solid tumors. This trial is being conducted by the National Cancer Institute (NCI), in collaboration with AstraZeneca and Cerulean. It is under the direction of NCI investigators, Anish Thomas, MBBS, M.D., Staff Clinician at the Thoracic and Gastrointestinal Oncology Branch of the Center for Cancer Research at the NCI, and Yves Pommier, M.D., Ph.D., an expert in DNA repair, and Chief of the Developmental Therapeutics Branch at the NCI.
CERU: 2.68 (-0.21)

Cerulean reports 1Q loss
Automated Insights - Mon May 02, 4:31PM CDT
WALTHAM, Mass. (AP) _ Cerulean Pharma Inc. (CERU) on Monday reported a loss of $13.5 million in its first quarter.
CERU: 2.68 (-0.21)

Cerulean Reports First Quarter 2016 Corporate Highlights and Financial Results
BusinessWire - Mon May 02, 3:06PM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended March 31, 2016.
CERU: 2.68 (-0.21)

Cerulean to Host First Quarter 2016 Conference Call on May 2
BusinessWire - Mon Apr 25, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the first quarter 2016 on May 2.
CERU: 2.68 (-0.21)

Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer
BusinessWire - Tue Apr 19, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the presentation of clinical data in a late-breaker at the 2016 American Association for Cancer Research (AACR) Annual Meeting. Adrian Senderowicz, M.D., Senior Vice President and Chief Medical Officer of Cerulean will present results from the first 18 patients enrolled in an investigator-sponsored trial.
CERU: 2.68 (-0.21)

Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.68 (-0.21), VVUS: 1.02 (-0.03), PETX: 7.52 (+0.02), GALE: 0.43 (-0.02)

Cerulean to Present at 15th Annual Needham Healthcare Conference
BusinessWire - Tue Apr 05, 6:00AM CDT
Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President & Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York on Tuesday, April 12 at 12:50 p.m. ET.
CERU: 2.68 (-0.21)

Cerulean Pharma (CERU) Jumps: Stock Moves 8.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:15AM CDT
Cerulean Pharma Inc (CERU) shares rose almost 9% in the last trading session.
CERU: 2.68 (-0.21), CALA: 3.04 (-0.11)

Nike and Newmont Mining fall; Pepco, Health Net rise
AP - Wed Mar 23, 3:55PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq stock market:
POM: 26.93 (+5.69), GILD: 80.29 (-0.17), NKE: 55.13 (-0.28), CERU: 2.68 (-0.21), FRED: 15.29 (-0.49), RHT: 72.75 (-2.07), NEM: 45.45 (+1.29), HNT: 67.19 (+2.38)

Top Penny Stocks On Wednesday March 23, 2016
ACCESSWIRE - Wed Mar 23, 12:24PM CDT
MIAMI, FL / ACCESSWIRE / March 23, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. BBLU, LUNA, CERU, and SFOR have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
LUNA: 1.34 (+0.01), CERU: 2.68 (-0.21), BBLU: 0.04 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 21

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 20

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 226

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 77

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 12

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading

Top 5 Most Recently Viewed Articles

STREAM Foundation Joins Forces with Greenwood Project for Growth

Updated Category News Views 138

STREAM Foundation Announces Exciting Collaboration The STREAM Foundation is thrilled to announce its upcoming merger with the Greenwood Project, a nationally renowned nonprofit dedicated to enhancing career pathways for underrepresented students. This strategic merger will significantly expand the breadth of resources and opportunities available to students interested in...

Continue Reading
Exploring the Future of Hydrogen Detection Technology and Growth

Updated Category News Views 545

Hydrogen Detection Market Size & Growth Insights The hydrogen detection market is on a remarkable trajectory, aiming to reach an impressive USD 642.39 million by 2032. This growth represents a substantial compound annual growth rate (CAGR) of 11.89% from 2024 to 2032, starting with a market valuation of USD 234.9 million in 2023. The ongoing emphasis on hydrogen as a...

Continue Reading
Ascletis Showcases Bold Moves in Obesity Drug Arena

Updated Category News Views 264

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Continue Reading
Top Precious Metal Stocks Impress Investors Amid Gold Surge

Updated Category News Views 326

Introduction to Precious Metals Stocks October has proven to be a prosperous month for precious metals stocks as they ascend into the upper echelons of market momentum rankings. This surge is primarily attributed to increased global demand, which is simultaneously boosting gold prices and favoring the miners’ positions. Gold's Resurgence Fuels Stock Momentum The recent...

Continue Reading
XTI Aerospace's Strategic Advancements and Financial Highlights

Updated Category News Views 156

XTI Aerospace's Significant Progress in Q3 2025 XTI Aerospace, Inc. (NASDAQ: XTIA) has made remarkable strides as a leader in vertical flight technologies. The company's innovative TriFan 600 aircraft is set to revolutionize commercial and defense aerospace applications. Recently, XTI announced its impressive achievements for the third quarter of 2025, marking a period...

Continue Reading